PL388513A1 - Zastosowanie oligonukleotydu siRNA - Google Patents

Zastosowanie oligonukleotydu siRNA

Info

Publication number
PL388513A1
PL388513A1 PL388513A PL38851309A PL388513A1 PL 388513 A1 PL388513 A1 PL 388513A1 PL 388513 A PL388513 A PL 388513A PL 38851309 A PL38851309 A PL 38851309A PL 388513 A1 PL388513 A1 PL 388513A1
Authority
PL
Poland
Prior art keywords
application
sirna oligonucleotide
sirna
oligonucleotide
Prior art date
Application number
PL388513A
Other languages
English (en)
Inventor
Monika Lamparska-Przybysz
Piotr Guzenda
Joanna Hucz
Maria Majorek
Aleksandra Stańczak
Maciej Wieczorek
Original Assignee
Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością filed Critical Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL388513A priority Critical patent/PL388513A1/pl
Priority to PCT/PL2010/000059 priority patent/WO2011008117A2/en
Publication of PL388513A1 publication Critical patent/PL388513A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL388513A 2009-07-12 2009-07-12 Zastosowanie oligonukleotydu siRNA PL388513A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL388513A PL388513A1 (pl) 2009-07-12 2009-07-12 Zastosowanie oligonukleotydu siRNA
PCT/PL2010/000059 WO2011008117A2 (en) 2009-07-12 2010-07-12 The use of a sirna oligonucleotide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL388513A PL388513A1 (pl) 2009-07-12 2009-07-12 Zastosowanie oligonukleotydu siRNA

Publications (1)

Publication Number Publication Date
PL388513A1 true PL388513A1 (pl) 2011-01-17

Family

ID=43450014

Family Applications (1)

Application Number Title Priority Date Filing Date
PL388513A PL388513A1 (pl) 2009-07-12 2009-07-12 Zastosowanie oligonukleotydu siRNA

Country Status (2)

Country Link
PL (1) PL388513A1 (pl)
WO (1) WO2011008117A2 (pl)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL378857A1 (pl) 2006-01-31 2007-08-06 Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością Podwójnie skręcone oligonukleotydy interferujące z mRNA genu WNT1 (siRNA) stosowane w celu hamowania poliferacji komórek nowotworowych
WO2008109518A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
KR100807069B1 (ko) * 2007-09-21 2008-02-25 고려대학교 산학협력단 암 치료용 의약 조성물

Also Published As

Publication number Publication date
WO2011008117A2 (en) 2011-01-20
WO2011008117A3 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
EP2424987A4 (en) ANTISENSE OLIGONUCLEOTIDES OF HEMOGLOBINS
IL196456A0 (en) Uderbelly of armord vehicle
ZA201202407B (en) Photobioreactor
GB0919264D0 (en) Oligonucleotide primers
EP2438246A4 (en) CONSTRUCTION ASPECTS
PL2502173T3 (pl) Projektowanie cząsteczek
GB201118187D0 (en) Photobioreactor
GB0915515D0 (en) Treatment of vasculoproliferative conditions
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
IL218683A0 (en) Prodrugs of guanfacine
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
IL226536A (en) DNA position-oriented change
ZA201003844B (en) Delivery of functional compounds
IL226537A (en) Position-directed change of DNA with oligonucleotides
TWM369719U (en) Clip structure of spoon
EP2501803A4 (en) PROCESS FOR PLURIPOTENZINTENSIVATION
GB0910078D0 (en) Uses of mannose-6-phosphate
EP2290063A4 (en) SIRNA FOR HUMAN OSTEOPONTIN
PL388513A1 (pl) Zastosowanie oligonukleotydu siRNA
TWM372743U (en) Improved structure of Kendama
TWM365675U (en) Improved structure of teapoy
EP2459540A4 (en) PREPARATION OF FIPAMEZOLE
GB0901863D0 (en) siRNA
GB201015091D0 (en) Enhanced delivery of sirna
GB201014935D0 (en) Enhanced delivery of siRNA

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)